GLS-1027 to Treat Anterior Uveitis in a Cavalier King Charles Spaniel Dog Volume 3 - Issue 1

Maslow Elizabeth A¹, Spertus Chloe B², Roberts Christine C³, Zipkin Robert E⁴ and Maslow Joel N⁵*

• ¹Comfort Cavaliers, Devon, Pennsylvania
• ²Metropolitan Veterinary Associates, Van Buren Ave., Norristown, Pennsylvania
• ³GeneOne Life Science, Pennsylvania Ave, Ft. Washington, Pennsylvania; Seoul, Korea
• ⁴MedChem, Davis, Rd Plymouth Meeting, Pennsylvania
• ⁵GeneOne Life Science, Pennsylvania Ave, Ft. Washington, Pennsylvania, and Seoul, Korea; Department of Medicine, Morristown Medical Center, Morristown, NJ

Received:January 29, 2021;   Published:February 10, 2021

Corresponding author: Maslow Joel N, GeneOne Life Science, Inc., Pennsylvania Ave., Ft. Washington PA 19034;

DOI: 10.32474/TOOAJ.2021.03.000157

 

Abstract PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Non-infectious, autoimmune anterior uveitis is a significant cause of ocular disease in both dogs, horses, and humans with the potential for significant vision loss. The mainstay of treatment is topical and/or systemic corticosteroids, however, animals, similar to humans, are not uncommonly resistant to therapy. Additionally, prolonged corticosteroid treatment may cause systemic and ocular toxicity. We describe here a case of steroid-resistant uveitis successfully treated with GLS-1027, an immunomodulatory compound that inhibits Th17 maturation and release of multiple inflammatory cytokines involved in the pathogenesis of uveitis. GLS-1027 may provide an alternative as a steroid-sparing therapeutic option.

Abstract| Introduction| Case Report| Discussion| References|